secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193125-24-252642
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date
--------------------------------------------------------------------------------

- Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.
- Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).
- Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.
- Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).
- R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/0001193125-24-252642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/d885289d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-252642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer